Trials / Completed
CompletedNCT00785044
Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 471 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | I-123 mIBG | This was an observational study. Participants were previously dosed in separate study. |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2010-01-01
- Completion
- 2010-02-01
- First posted
- 2008-11-05
- Last updated
- 2017-04-26
- Results posted
- 2017-04-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00785044. Inclusion in this directory is not an endorsement.